Profound Medical (PROF) EBITDA (2024 - 2026)

Profound Medical's EBITDA history runs 3 years deep, the most recent figure standing at -$8.0 million for Q1 2026.

• On a quarterly basis, EBITDA rose 28.17% year-over-year to -$8.0 million in Q1 2026; TTM through Mar 2026 was -$38.1 million, a 4.84% decrease from a year earlier, with the FY2025 full-year figure at -$41.3 million, down 24.78% from the prior year.
• EBITDA declined to -$8.0 million in Q1 2026 per PROF's latest filing, from -$7.4 million in the prior quarter.
• Across five years, EBITDA topped out at -$7.4 million in Q4 2025 and bottomed at -$13.8 million in Q2 2025.
• The 3-year median for EBITDA is -$8.3 million (2024), against an average of -$9.1 million.
• Across the five-year window, EBITDA tumbled 76.05% in 2025 and rose 28.17% in 2026, its largest moves.
• Year by year, EBITDA stood at -$8.3 million in 2024, then increased by 11.7% to -$7.4 million in 2025, then declined by 8.85% to -$8.0 million in 2026.
• Per Business Quant, the three latest PROF EBITDA figures stand at -$8.0 million (Q1 2026), -$7.4 million (Q4 2025), and -$8.9 million (Q3 2025).